Literature DB >> 24190005

Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis.

Elisa Borsani1, Alessandra Majorana2, Marco Angelo Cocchi1, Giulio Conti3, Sara Bonadeo2, Alessandro Padovani4, Giuseppe Lauria5, Elena Bardellini2, Rita Rezzani1, Luigi Fabrizio Rodella6.   

Abstract

Burning mouth syndrome (BMS) is an intra-oral burning sensation for which presently no medical or dental causes have been found, and in which the oral mucosa appears normal. It remains an unknown disease for which there is still no long-term treatment. The aim of this study was to assess the epithelial alteration of transient receptor potential vanilloid channel type 1 (TRPV1) and cannabinoid receptors type 1 (CB1) and type 2 (CB2) in the human tongue. The study was performed on eight healthy controls and eight BMS patients. All patients underwent a 3-mm punch biopsy at the anterolateral aspect of the tongue close to the tip. TRPV1, CB1 and CB2 immuno-histochemistry was carried out showing an altered expression of all receptors. In BMS patients there was increased TRPV1, decreased CB1 and increased CB2 expression in tongue epithelial cells also associated with a change in their distribution. It would appear that these receptors are related to BMS. These data could be useful for future characterization of BMS epithelial markers and therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24190005     DOI: 10.14670/HH-29.10.523

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

Review 1.  Is it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms.

Authors:  Hawra Aljanobi; Amarpreet Sabharwal; Bralavan Krishnakumar; Jill M Kramer
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-01-24

2.  Impaired Junctions and Invaded Macrophages in Oral Epithelia With Oral Pain.

Authors:  Reiko U Yoshimoto; Reona Aijima; Yukiko Ohyama; Junko Yoshizumi; Tomoko Kitsuki; Yasuyoshi Ohsaki; Ai-Lin Cao; Atsushi Danjo; Yoshio Yamashita; Tamotsu Kiyoshima; Mizuho A Kido
Journal:  J Histochem Cytochem       Date:  2018-11-19       Impact factor: 2.479

3.  Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial.

Authors:  Giulia Ottaviani; Katia Rupel; Margherita Gobbo; Augusto Poropat; Valentina Zoi; Michela Faraon; Roberto Di Lenarda; Matteo Biasotto
Journal:  Clin Oral Investig       Date:  2018-10-25       Impact factor: 3.573

4.  Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial.

Authors:  Begoña Palacios-Sánchez; Luis-Alberto Moreno-López; Rocío Cerero-Lapiedra; Silvia Llamas-Martínez; Germán Esparza-Gómez
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-07-01

5.  Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome.

Authors:  Dimos D Mitsikostas; Srdjan Ljubisavljevic; Christina I Deligianni
Journal:  J Headache Pain       Date:  2017-03-29       Impact factor: 7.277

6.  Efficacy of the photobiomodulation therapy in the treatment of the burning mouth syndrome.

Authors:  E Bardellini; F Amadori; G Conti; A Majorana
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2019-11-01

7.  Unpleasant olfactory and gustatory stimuli increase pain unpleasantness in patients with chronic oral burning pain: An exploratory study.

Authors:  Angela Sandri; Maria Paola Cecchini; Alice Zanini; Riccardo Nocini; Federico Boschi; Giovanni Zanette; Alessandro Marcon; Mirta Fiorio; Michele Tinazzi
Journal:  Eur J Pain       Date:  2022-03-17       Impact factor: 3.651

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.